Immunic appoints Tamara A. Seymour as Interim CFO
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
“Ms. Seymour has a proven track record of guiding public and privately-held life sciences companies through their corporate life cycles, including capital raising, negotiating complex strategic transactions, setting and maintaining internal fiscal policy and driving revenue growth,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “Her range of expertise and relevant leadership skills will serve us well as we drive the development of our lead compound, IMU-838, now in phase 2 clinical trials for ulcerative colitis and relapsing-remitting multiple sclerosis, as well as our other pipeline assets.”
Since 2018, Ms. Seymour has served as a financial advisor, assisting life sciences companies with merger and acquisition activities and other finance-related needs. From 2014 to 2017, she served as Chief Financial Officer of Signal Genetics Inc. (now miRagen Therapeutics, Inc.), a publicly traded commercial-stage, molecular genetic diagnostics company focused on multiple myeloma. From 2010 to 2014, Ms. Seymour served as Chief Financial Officer of Hemaquest Pharmaceuticals, Inc., a venture-backed clinical development stage biotechnology company developing proprietary small molecules for the treatment of life-threatening hematologic disorders. From 2001 to 2009, Ms. Seymour served as Chief Financial Officer of Favrille, Inc. (now MMR Global, Inc.), a publicly traded clinical development stage biopharmaceutical company developing therapeutic vaccines for non-Hodgkin’s lymphoma.
She is currently a member of the board of directors and audit committee chair of Beacon Discovery, Inc., a privately-held company working to identify and advance molecules targeting G protein-coupled receptors.